Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 1
1982 1
1988 1
1990 1
1993 1
2004 1
2008 4
2009 5
2010 1
2011 1
2012 1
2013 2
2014 4
2015 1
2016 4
2017 3
2018 2
2019 1
2020 2
2021 3
2022 9
2023 5
2024 3
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Comparison of the efficacy of febuxostat vs. benzbromarone in the treatment of gout: a meta-analysis in Chinese gout patients.
Yan CQ, Liang C, Lan ZR, Su C, Xiong SY, Yang YX, Chen JM, Tang SL, Huang JS, Zhang ZH, Luo MJ, Xiao ZH. Yan CQ, et al. Eur Rev Med Pharmacol Sci. 2023 Dec;27(24):11988-12003. doi: 10.26355/eurrev_202312_34797. Eur Rev Med Pharmacol Sci. 2023. PMID: 38164861 Free article.
This meta-analysis aimed to compare the efficacy of febuxostat and benzbromarone in the treatment of gout. MATERIALS AND METHODS: PubMed, Embase, and the Cochrane Library were searched for articles related to febuxostat and benzbromarone in the treatment of gout fro …
This meta-analysis aimed to compare the efficacy of febuxostat and benzbromarone in the treatment of gout. MATERIALS AND METHODS: Pub …
Comparison of the efficacy and safety of benzbromarone and febuxostat in gout and hyperuricemia: a systematic review and meta-analysis.
Wu F, Chen L, Du Y. Wu F, et al. Clin Rheumatol. 2024 May;43(5):1745-1754. doi: 10.1007/s10067-024-06933-4. Epub 2024 Mar 16. Clin Rheumatol. 2024. PMID: 38492092
However, the divergent efficacy and safety between febuxostat and the traditional ULT drug, benzbromarone, remain poorly understood. This knowledge gap necessitates a comprehensive analysis and evidence update to guide drug selection for physicians and patients. ...CONCLUS …
However, the divergent efficacy and safety between febuxostat and the traditional ULT drug, benzbromarone, remain poorly understood. …
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials.
Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P, Chaiyakunapruk N, McKay G, Attia J, Thakkinstian A. Sapankaew T, et al. BMC Nephrol. 2022 Jun 23;23(1):223. doi: 10.1186/s12882-022-02850-3. BMC Nephrol. 2022. PMID: 35739495 Free PMC article.
Randomized controlled trials (RCT) of adults with asymptomatic hyperuricemia were eligible if they compared any pair of ULTs (i.e., allopurinol, febuxostat, probenecid, benzbromarone, sulfinpyrazone, rasburicase, lesinurad, and topiroxostat) and placebo or no ULT, and had …
Randomized controlled trials (RCT) of adults with asymptomatic hyperuricemia were eligible if they compared any pair of ULTs (i.e., allopuri …
Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function.
Ke J, Pan J, Lin H, Han Z, Gu J. Ke J, et al. Curr Med Res Opin. 2023 Jul;39(7):947-953. doi: 10.1080/03007995.2023.2223916. Epub 2023 Jun 21. Curr Med Res Opin. 2023. PMID: 37300510 Clinical Trial.
RESULTS: After a median of 23.5 months' follow-up (16-30 months), the primary endpoint reflected by E/e' in benzbromarone group reached a significant improvement when compared to control group (p <.001). Composite endpoints occurred in 11 patients of the control group w …
RESULTS: After a median of 23.5 months' follow-up (16-30 months), the primary endpoint reflected by E/e' in benzbromarone group reach …
Superiority of Low-Dose Benzbromarone Add-On to Low-Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined-Type Hyperuricemia.
Xue X, Sun M, Yan F, Dalbeth N, He Y, Li X, Qi H, Chen Y, Yuan X, Li M, Ji A, Terkeltaub R, Li C. Xue X, et al. Arthritis Care Res (Hoboken). 2024 May;76(5):703-711. doi: 10.1002/acr.25283. Epub 2024 Feb 20. Arthritis Care Res (Hoboken). 2024. PMID: 38130040 Free PMC article. Clinical Trial.
We report a comparative effectiveness trial of febuxostat monotherapy versus benzbromarone add-on to low-dose febuxostat in gout specifically with combined renal urate underexcretion and overload. METHODS: A prospective randomized trial was conducted on patients with combi …
We report a comparative effectiveness trial of febuxostat monotherapy versus benzbromarone add-on to low-dose febuxostat in gout spec …
Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Hosoya T, et al. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):62-70. doi: 10.1007/s10157-020-01849-0. Epub 2020 Jan 24. Clin Exp Nephrol. 2020. PMID: 31980978 Free PMC article. Clinical Trial.
This study was conducted to compare the efficacy and safety of dotinurad with those of benzbromarone. METHODS: In this 14-week, randomized, multicenter, double-blind, parallel-group, dose escalation, benzbromarone-controlled, phase 3 study, hyperuricemic patients wi …
This study was conducted to compare the efficacy and safety of dotinurad with those of benzbromarone. METHODS: In this 14-week, rando …
Effects of benzbromarone and allopurinol on adiponectin in vivo and in vitro.
Inokuchi T, Tsutsumi Z, Takahashi S, Ka T, Yamamoto A, Moriwaki Y, Masuzaki H, Yamamoto T. Inokuchi T, et al. Horm Metab Res. 2009 Apr;41(4):327-32. doi: 10.1055/s-0028-1102947. Epub 2008 Dec 1. Horm Metab Res. 2009. PMID: 19048458 Clinical Trial.
When treating gout patients, we have incidentally found elevated serum levels of adiponectin in some after administration of benzbromarone. In the present study, we determined whether benzbromarone increases the serum level of adiponectin in gout patients and invest …
When treating gout patients, we have incidentally found elevated serum levels of adiponectin in some after administration of benzbromaron …
Superiority of Low-Dose Benzbromarone to Low-Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion.
Yan F, Xue X, Lu J, Dalbeth N, Qi H, Yu Q, Wang C, Sun M, Cui L, Liu Z, He Y, Yuan X, Chen Y, Cheng X, Ma L, Li H, Ji A, Hu S, Ran Z, Terkeltaub R, Li C. Yan F, et al. Arthritis Rheumatol. 2022 Dec;74(12):2015-2023. doi: 10.1002/art.42266. Epub 2022 Nov 11. Arthritis Rheumatol. 2022. PMID: 35795968 Free PMC article. Clinical Trial.
This comparative effectiveness clinical trial was undertaken to compare first-line nontitrated low-dose benzbromarone (LDBen) uricosuric therapy to XOI ULT with low-dose febuxostat (LDFeb) in gout patients with renal uric acid underexcretion. ...
This comparative effectiveness clinical trial was undertaken to compare first-line nontitrated low-dose benzbromarone (LDBen) uricosu …
Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial.
Kohagura K, Satoh A, Kochi M, Nakamura T, Zamami R, Tana T, Kinjyo K, Funakoshi R, Yamazato M, Ishida A, Sakima A, Iseki K, Arima H, Ohya Y. Kohagura K, et al. J Hypertens. 2023 Sep 1;41(9):1420-1428. doi: 10.1097/HJH.0000000000003484. Epub 2023 Jun 8. J Hypertens. 2023. PMID: 37334544 Clinical Trial.
They were randomized to receive febuxostat ( n = 47; febuxostat group) or benzbromarone ( n = 48; benzbromarone group) and titrated to reduce their serum urate level to <6.0 mg/dl. ...CONCLUSIONS: No significant differences were found in the effects of febuxost …
They were randomized to receive febuxostat ( n = 47; febuxostat group) or benzbromarone ( n = 48; benzbromarone group) and t …
Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid.
Schepers GW. Schepers GW. J Int Med Res. 1981;9(6):511-5. doi: 10.1177/030006058100900615. J Int Med Res. 1981. PMID: 7033016 Clinical Trial.
The purpose of this study was to compare the serum uric acid lowering effect of benzbromarone (Minuric), allopurinol, probenecid and placebo in patients suffering from confirmed hyperuricaemia. ...For the six trialists it was found that benzbromarone is superior to …
The purpose of this study was to compare the serum uric acid lowering effect of benzbromarone (Minuric), allopurinol, probenecid and …
51 results